🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

7 recruiting trials

for NSCLC (Non-small Cell Lung Cancer)R

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation NCT07809256Phase 31 site📍 Saint Petersburg EuroCityClinic LLC · Tests: lenvatinib pembrolizumab Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: LMV-12(HE003) Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC NCT05669846Phase 21 site📍 Pittsburgh Diwakar Davar · Tests: Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC NCT06303505Phase 1, Phase 229 sites📍 Birmingham📍 New Haven📍 Atlanta Gilead Sciences · Tests: TUB-040
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy